Patrick54
Established Member
- Reaction score
- 3
Does this mean the dark side may not be the dark side anymore? :doctor:
http://clinicaltrials.gov/ct2/show/NCT0 ... 22&rank=11
http://clinicaltrials.gov/ct2/show/NCT0 ... 22&rank=11
sir chugalot said:I guess for me the most notable thing is the geographical spread, which suggest more than just mild curiosity on the part of Glaxo.
Russia, Thailand, Argentina? This is no small study.
Also they're only interested in Norwood III V's to Norwood 5s.
I'd always thought dutasteride carried more risk than finasteride, so given the bad publicity around finasteride lately, i'm surprised Glaxo are doing this, unless they know something we don't.
Patrick54 said:I'm not sure, it looks like they want to re-compare dutasteride to finasteride and this may lead to further testing hopefully getting dutasteride approved for male pattern baldness.
Bryan said:Patrick54 said:I'm not sure, it looks like they want to re-compare dutasteride to finasteride and this may lead to further testing hopefully getting dutasteride approved for male pattern baldness.
Glaxo has already stated emphatically in the past that they aren't going for FDA approval of dutasteride as an male pattern baldness treatment, but that apparently doesn't mean that they aren't interested in doing additional trials of it for that purpose in foreign countries. I imagine they want to keep up worldwide interest in the drug just so that doctors will use it off-label for that purpose, even here in America.
